← Leaderboards
Scott Evan Millman
Sloan-Kettering Inst Can Research
$618,228
Attributed
$618,228
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $206.1K · FY2022–24$250K$187.5K$125K$62.5K$0
'22
'23
'24
Funding mix
By agency
NIH$618,228 · 1
By mechanism
K08$618,228 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Omar Abdel-Wahab$18,758,829
- Michael Kharas$18,485,709
- Andrew Michael Intlekofer$5,190,407
- Ingo K Mellinghoff$6,692,369
- Ping Chi$18,562,542
Others in their field
Other Rising Stars on “Dioxygenases”
- Junwei Shi · University Of Pennsylvania$1,477,105
- Bianca Denise Santomasso · Sloan-Kettering Inst Can Research$1,262,391
- Stefanie Avril · Case Western Reserve University$1,123,897
- Jianqin Lu · University Of Arizona$1,016,541
- Diana Shi · Dana-Farber Cancer Inst$1,011,306
- Ping Yin · Northwestern University$921,505
Research focus
DioxygenasesAdverse OutcomeAlpha KetoglutarateAcute Myelocytic LeukemiaBiochemistryBiologicalBone MarrowCancer GeneticsAcute Myeloid Leukemia CellCareer DevelopmentCell LineCellsCharacteristicsChemotherapyChromatinChromosome AbnormalityCitric Acid CycleClinical PracticeCareerComplexCrispr/Cas TechnologyCytotoxicityDevelopment PlansDna Methylation
Grant awards (3)
Exploiting alpha-ketoglutarate-dependent metabolism for therapeutic benefit in acute myeloid leukemia$206,076
K08 · FY2024 · CA · contact PI
Exploiting alpha-ketoglutarate-dependent metabolism for therapeutic benefit in acute myeloid leukemia$206,076
K08 · FY2023 · CA · contact PI
Exploiting alpha-ketoglutarate-dependent metabolism for therapeutic benefit in acute myeloid leukemia$206,076
K08 · FY2022 · CA · contact PI